Skip to main content

GSK Resolves Zantac Cancer Claims

GSK Resolves Zantac Cancer Claims

Introduction

GlaxoSmithKline has recently reached a settlement agreement in California state court with four plaintiffs who had filed lawsuits related to Zantac, a heartburn drug that was recalled in 2019 due to its association with cancer.

The lawsuits alleged that the use of Zantac, which contained the unstable active pharmaceutical ingredient ranitidine, resulted in the development of cancer, particularly due to the presence of the carcinogenic chemical byproduct N-Nitrosodimethylamine (NDMA).

Over the past four years, various companies, including GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Sanofi, and others involved in the sale of both brand name and generic ranitidine pills, have faced legal actions from individuals who claim to have been diagnosed with cancer and other injuries linked to NDMA exposure.

Initially, most of the litigation was consolidated in the federal court system, with all Zantac cancer lawsuits centralized in the U.S. District Court for the Southern District of Florida for coordinated discovery and pretrial proceedings. However, a controversial ruling issued by the judge last year excluded all plaintiffs' expert witnesses from testifying at trial, making it challenging for federal plaintiffs to prove that Zantac caused their cancer. This led to the dismissal of all Zantac lawsuits pending in the federal court system.

It is important to note that this federal ruling does not affect Zantac lawsuits filed in California and other state courts, where different standards for the admissibility of expert witness testimony are applied. Therefore, cases in state courts continue to address the allegations brought forth by Zantac users who claim that the drug led to their cancer diagnoses.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Study Links Roundup Chemical to Long-Term Brain Damage

Categories: Roundup

A recent study suggests that exposure to the widely used herbicide Roundup, which contains the active ingredient glyphosate, may be…

Zimmer Biomet Gets FDA Approval for Cementless Partial Knee

Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…

Court Names Special Masters for Bard Mesh Claim Settlements

Categories: Hernia Mesh

The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…

Demand Letter or Medical Record Review?     
Free Trials + 10% Discount!